Xuan-mai T. Thanh-Truong
Boulogne-billancourt, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
Journal: Oncology and therapy
Published: May 30, 2024
Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Journal: Advances in therapy
Published: October 31, 2022
Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Journal: Advances in therapy
Published: March 29, 2022
Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Journal: Advances in therapy
Published: October 29, 2021
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2021
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
Journal: Anti-cancer drugs
Published: January 25, 2020
Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).
Journal: Advances in therapy
Published: January 22, 2020
Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies.
Journal: Advances in therapy
Published: January 19, 2020
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Journal: European journal of nuclear medicine and molecular imaging
Published: September 20, 2019
Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies.
Journal: Advances in therapy
Published: August 07, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026